Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Luminice-203 yields its first topline data, but where are all the patients?
Pfizer moves to take PF-07934040 into its first clinical trial.
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
